Table 1 Baseline characteristics of patients.

From: Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication

Number of patients

567

Sex, Male n(%)

259 (45.7)

Age (years old)

66 (16–92)

BMI (kg/m2)†

22.8 (12.8–46.5)

Liver cirrhosis n(%)

77 (13.6)

HCV genotype (1/2/Mix/Others/unknown)

359/195/7/4/2

Diabetes, n(%)

105 (18.5)

Therapy resume n(%)

 

  DCV + ASV

98 (17.3)

  SOF/LDV

153 (27.0)

  OMV/PTV/r

30 (5.3)

  EBR + GZR

33 (5.8)

  DCV + ASV + BCV

5 (0.9)

  GLE/PIB

91 (16.0)

  SOF + RBV

145 (25.6)

  SOF/VEL

3 (0.5)

  SOF/LDV + RBV

7 (1.2)

  Others

2 (0.4)

Platelet (× 104/µl)

16.5 (0.7–41.3)

AST (IU/L)

40 (10–342)

ALT (IU/L)

38 (5–389)

GGT (IU/L)‡

33 (8–777)

Albumin (g/dl)

4.1 (2.4–5.0)

AFP (ng/ml)

4.2 (1.0–250.8)

Type4 collagen 7S (ng/ml)§

4.8 (1.5–17.0)

Hyaluronic acid (ng/ml)

103 (3.2–6660)

WFA + Mac-2 Binding protein (C.O.I)††

1.81 (0.19–20.0)

FIB4 index

2.72 (0.29–82.8)

LSM (kPa)

7.1 (2.9–66.4)

CAP (db/m)‡‡

219 (100–486)

Median obsevation period from start of treatment (Months)

50.2 (7–92)

  1. † The data include only 441 patients, ‡ The data include only 355 patients.
  2. § The data include only 233 patients, The data include only 327 patients.
  3. †† The data include only 431 patients, ‡‡ The data include only 332 patients.
  4. BMI Body mass index, HCV Hepatitis C virus, DCV daclatasvir, ASV asnerprevier, SOF/LDV sofosbuvir/ledipasvir, OMV/PTV/r ombitasvir/paritaprevir/ritonavir, EBR Elbasvir, GZR Grazoprevir, BCV Beclabuvir, GLE/PIB Glecaprevir/Pibrentasvir, RBV Ribavirin, SOF/VEL sofosbuvir/velpatasvir, AST Aspartate transaminase, ALT Alanine aminotransferase, GGT γ-glutamyltransferase, AFP α-fetoprotein, WFA Wisteria floribunda agglutinin, LSM Liver stiffness measurement, CAP Controlled attenuation Parameter.
Back to article page